Skip to main content

Immunology vs Dermatology — Deal Terms Comparison

Immunology Median Upfront
$480M
Total: $2.5B
Dermatology Median Upfront
$393M
Total: $2.1B
Immunology Royalties
13.2%-22.1%
Tiered to 26.1%
Dermatology Royalties
6.5%-13.1%
Tiered to 17.1%

Market Analysis

Immunology and Dermatology represent distinct licensing landscapes with different risk-reward dynamics. Phase 2 immunology deals carry a median total deal value of $2.5B with $480M upfront, compared to $2.1B total value and $393M upfront for dermatology. The differences reflect divergent clinical development timelines, regulatory pathways, and addressable market sizes.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do immunology and dermatology deal terms compare?
Immunology Phase 2 deals average $2.5B total value ($480M upfront), while Dermatology deals average $2.1B ($393M upfront). The differences are driven by addressable market size, clinical development complexity, and regulatory pathway characteristics.
PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.

or
Unlock Everything — $299/mo Pro

7-day money-back guarantee · Cancel anytime

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.

Start Calculating